

Medifast Inc. (MED)

NYSE; consumer nondurables; SIC 2090, Miscellaneous Food Preparations & Kindred Products; CIK 0000910329

Medifast Inc. MED; consumer nondurables	
Grade	A/B A B C D E on the A/B boundary of 124 graded peers percentile 22.0; sampling error 3.8 points; lower is stronger
Rank	28 of 124
Profitability	A percentile 15.8
Solvency	A percentile 8.8
Growth and financing	E percentile 84.5
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$248.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Feb 17, 2026 234 days before the rescan; latest periodic filing 10-Q received Aug 3, 2026
Last close	\$11.46 2026-10-08; market equity \$128.1M
Price used in grade	None



A/B, the bull
on the A/B boundary of its sector; letters are fifths of the 124 graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: B from Aug 21, 2026, A/B from Sep 26, 2026, B from Oct 3, 2026, A/B from Oct 7,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

Medifast, Inc. ("Medifast," the "Company," "we" or "us") is the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system. As we enter 2026, the Company is moving from transformation to execution, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. Medifast's approach focuses on addressing the root cause of metabolic

dysfunction.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 15.8						
Gross profitability		111.0%	29.8%	2.1	146	2025-12-31
Return on invested capital		not computable	5.6%			one or more required annual facts are missing
Accruals ratio		(9.6%)	(5.0%)	26.3	153	2025-12-31
Gross margin stability, five years		1.1 pts	1.9 pts	19.1	116	2025-12-31
Solvency, sleeve percentile 8.8						
Twelve-month failure probability		0.02%	0.03%	16.7	7	2026-06-30
Altman Z double-prime		10.15	3.11	3.3	122	2025-12-31
Net debt to EBITDA		not computable	2.54x			one or more required annual facts are missing
Interest coverage		not computable	2.51x			latest aligned inputs end 2011-12-31; latest annual assets end 2025-12-31
Current ratio		4.69x	1.81x	6.4	157	2025-12-31
Growth and financing, sleeve percentile 84.5						
Revenue growth, three-year compound		(37.7%)	0.2%	98.5	133	2025-12-31
Free cash flow growth, three-year compound		(80.9%)	14.9%	100.0	66	2025-12-31
Reinvestment rate		not computable	10.7%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(7.8%)	0.5%	80.5	134	2025-12-31
Net share issuance, one year		0.5%	0.05%	59.2	104	2026-02-10

Among 124 peers

consumer nondurables; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
------	---------	------------	--------	----------

23	Daily Journal Corp. (DJCO)	17.9	A/B late filer, fortress balance sheet
24	Cintas Corp. (CTAS)	18.7	A/B
25	Brown Forman Corp. (BF-A)	19.9	A/B
26	Brown Forman Corp. (BF-B)	19.9	A/B
27	Simply Good Foods Co. (SMPL)	21.1	A/B
28	Medifast Inc. (MED) <	22.0	A/B
29	Mattel Inc. (MAT)	22.8	A/B
30	Superior Group OF Companies, Inc. (SGC)	23.6	A/B
31	Turning Point Brands, Inc. (TPB)	24.4	B
32	Tapestry, Inc. (TPR)	25.2	B
33	Mission Produce, Inc. (AVO)	26.0	B

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(11.2%)	(0.2%)	33
Distance from 52-week high	(18.5%)	(24.8%)	63
EBIT to enterprise value	not computable	4.1%	
Free cash flow yield	1.0%	4.8%	26
Book value to price	1.54	0.57	86
Sales to price	3.02	1.20	83
Composite equity issuance, five years	(17.9%)	(16.3%)	40
Relative strength against the sector, log excess return	(0.21)	(0.10)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$71.9M
Operating cash flow, four quarters	\$8.8M
Months of runway	not finite
Days since last periodic filing	67 (10-Q received Aug 3, 2026)
Median daily dollar volume, 63 sessions	\$1.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$275.2M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
2	assets	us-gaap:Assets	\$248.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
3	net income	us-gaap:NetIncomeLoss	-\$18.7M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$6.9M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
5	assets	us-gaap:Assets	\$284.2M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$385.8M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
7	gross profit	us-gaap:GrossProfit	\$444.6M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$602.5M	2024-12-31	2026-02-17	10-K	0001628280-26-008656

9	gross profit	us-gaap:GrossProfit	\$775.9M	2023-12-31	2026-02-17	10-K	0001628280-26-008656
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2023-12-31	2026-02-17	10-K	0001628280-26-008656
11	gross profit	us-gaap:GrossProfit	\$1.1B	2022-12-31	2025-02-18	10-K	0001628280-25-006094
12	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$1.6B	2022-12-31	2023-02-21	10-K	0001628280-23-004341
13	gross profit	us-gaap:GrossProfit	\$1.1B	2021-12-31	2024-02-20	10-K	0001628280-24-005620
14	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$1.5B	2021-12-31	2023-02-21	10-K	0001628280-23-004341
15	current assets	us-gaap:AssetsCurrent	\$201.7M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
16	current liabilities	us-gaap:LiabilitiesCurrent	\$43.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$158.3M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
18	operating income	us-gaap:OperatingIncomeLoss	-\$14.2M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
19	book equity	us-gaap:StockholdersEquity	\$198.9M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
20	liabilities	us-gaap:Liabilities	\$49.1M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
21	operating income	us-gaap:OperatingIncomeLoss	\$27.4M	2011-12-31	2014-03-17	10-K	0001144204-14-016118
22	interest expense	us-gaap:InterestExpense	\$102,000	2011-12-31	2012-03-15	10-K	0001144204-12-015310
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.6M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$24.5M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.5M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$147.7M	2023-12-31	2026-02-17	10-K	0001628280-26-008656
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.5M	2023-12-31	2026-02-17	10-K	0001628280-26-008656
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$194.6M	2022-12-31	2025-02-18	10-K	0001628280-25-006094
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$16.7M	2022-12-31	2025-02-18	10-K	0001628280-25-006094
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$14.2M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$55.6M	2023-12-31	2026-02-17	10-K	0001628280-26-008656
32	income tax	us-gaap:IncomeTaxExpenseBenefit	\$13.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008656
33	current assets	us-gaap:AssetsCurrent	\$214.4M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
34	current liabilities	us-gaap:LiabilitiesCurrent	\$64.2M	2024-12-31	2026-02-17	10-K	0001628280-26-008656
35	assets	us-gaap:Assets	\$309.9M	2023-12-31	2025-02-18	10-K	0001628280-25-006094
36	assets	us-gaap:Assets	\$316.2M	2022-12-31	2024-02-20	10-K	0001628280-24-005620
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,991,273	2026-02-10	2026-02-17	10-K	0001628280-26-008656
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,937,830	2025-02-11	2025-02-18	10-K	0001628280-25-006094